Vaccines
•47 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (47)
| Company | Market Cap | Price |
|---|---|---|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$215.90B |
$85.99
-0.34%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$140.14B |
$24.66
+1.50%
|
|
CVS
CVS Health Corporation
CVS administers vaccines across its pharmacy network, a direct service offering.
|
$99.12B |
$78.16
+1.91%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$64.15B |
$144.07
+0.33%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda markets vaccines (QDENGA) and maintains a vaccines-focused portfolio.
|
$42.61B |
$13.44
+1.59%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$24.91B |
$103.92
-0.72%
|
|
RDY
Dr. Reddy's Laboratories Limited
Strategic emphasis on vaccines, including RSV vaccine programs.
|
$11.09B |
$13.30
-1.12%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.00B |
$22.14
-1.91%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$10.50B |
$27.16
-3.50%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$5.84B |
$45.29
+1.21%
|
|
IBRX
ImmunityBio, Inc.
Vaccine vectors and vaccines pipeline (hAd5 vectors targeting TAAs).
|
$2.12B |
$2.39
+1.27%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.70B |
$42.10
+0.59%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.36B |
$8.41
-0.24%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.23B |
$10.25
-1.44%
|
|
CVAC
CureVac N.V.
The company is actively developing infectious disease vaccines using its mRNA backbone (Vaccines).
|
$1.20B |
$5.34
-0.37%
|
|
OPK
OPKO Health, Inc.
OPKO is advancing vaccines via EBV vaccine collaboration, a core vaccine development activity.
|
$1.08B |
$1.34
-7.88%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$665.82M |
$12.48
-2.80%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$643.86M |
$9.56
+4.71%
|
|
OCGN
Ocugen, Inc.
OCU500 represents an inhaled mucosal vaccine platform with a COVID-19 vaccine IND.
|
$455.57M |
$1.55
+4.73%
|
|
AHG
Akso Health Group
Vaccine research centers planned (AIDS and Covid-19) within the strategy.
|
$388.28M |
$1.60
-4.29%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax-L and DCVax-Direct are therapeutic vaccines for cancer, aligning with Vaccines.
|
$355.83M |
$0.25
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor is developing a vaccine candidate via its StealthX platform in collaboration with Project NextGen.
|
$297.56M |
$6.53
+5.07%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$270.39M |
$9.98
+3.69%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is a WT1-targeted cancer vaccine, fitting the Vaccines category as a therapeutic vaccine approach.
|
$181.60M |
$1.81
-5.24%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$148.61M |
$9.32
+0.76%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-801 is a live virus vaccine candidate for mpox/smallpox, placing Tonix in vaccines development with potential commercialization.
|
$136.39M |
$18.65
+3.27%
|
|
ANIX
Anixa Biosciences, Inc.
Breast and ovarian cancer vaccines constitute a direct vaccine product line.
|
$133.03M |
$4.13
+1.72%
|
|
TVGN
Tevogen Bio Holdings Inc.
TVGN 489 and the TVGN vaccine program indicate vaccine development capabilities (T cell vaccine approach).
|
$115.56M |
$0.62
+3.48%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oravax Medical Inc., in which Oramed holds a majority stake, focuses on oral vaccines, making Vaccines a direct product category for the company.
|
$97.63M |
$2.38
-1.04%
|
|
INO
Inovio Pharmaceuticals, Inc.
Pipeline includes Ebola vaccine booster (INO-4201) and other vaccine approaches; company develops vaccines using DNA plasmids.
|
$86.18M |
$2.35
-0.64%
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$76.27M |
$0.33
|
|
FBIO
Fortress Biotech, Inc.
Fortress’ portfolio includes vaccine programs (Helocyte's Triplex CMV vaccine), aligning with Vaccines.
|
$75.70M |
$2.56
-0.19%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$68.52M |
$1.04
+21.20%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Vaccines program (universal dengue vaccine) as an internal asset and potential product.
|
$61.43M |
N/A
|
|
BRNS
Barinthus Biotherapeutics plc
Pipeline includes vaccines (VTP-500 MERS) and vaccine-focused platforms.
|
$53.13M |
$1.30
+1.16%
|
|
PDSB
PDS Biotechnology Corporation
PDS0101/Versamune HPV functions as a therapeutic cancer vaccine, aligning with the Vaccines category.
|
$42.74M |
$0.93
-2.53%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Strategic collaboration on thermostable vaccines indicates vaccine development activity.
|
$36.47M |
$2.45
-0.81%
|
|
DYAI
Dyadic International, Inc.
Company has vaccine-related programs and antigen work (e.g., mpox ferritin nanoparticle vaccine antigen) via its platforms, aligning with vaccines.
|
$34.00M |
$1.14
-2.56%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN311 and PMN400 indicate a vaccine development program targeting amyloid and alpha-synuclein epitopes.
|
$13.57M |
$0.42
+0.29%
|
|
IMRN
Immuron Limited
Travelan IMM-124E prophylactic product aligns with vaccines/immune prophylaxis category.
|
$10.83M |
$1.91
-5.45%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$8.60M |
$0.55
-1.65%
|
|
BCTX
BriaCell Therapeutics Corp.
Bria-IMT Bria-OTS involve cellular vaccine approaches in cancer, aligning with Vaccines.
|
$7.45M |
$11.83
+4.14%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 is described as a vaccine-based active immunotherapy approach for Alzheimer's.
|
$7.33M |
$2.63
+0.96%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$6.22M |
$5.81
+0.87%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$5.06M |
$1.55
+2.98%
|
|
IMNN
Imunon, Inc.
PlaCCine platform includes DNA-based vaccines (e.g., COVID-19 candidate), aligning with Vaccines.
|
$4.43M |
$4.54
+1.22%
|
Loading company comparison...
Loading industry trends...
Loading research report...
